Standout Papers
Citation Impact
Citing Papers
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
2008 Standout
Predicting Survival in Pulmonary Arterial Hypertension
2010 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Bosentan Therapy in Patients With Eisenmenger Syndrome
2006
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
2019 StandoutNobel
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
2018 Standout
Tadalafil Therapy for Pulmonary Arterial Hypertension
2009 Standout
Pulmonary hypertension associated with benfluorex exposure
2012
A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology
2007
Long-Term Bosentan in Chronic Thromboembolic Pulmonary Hypertension
2006
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
2009
The concept of “baby lung”
2005
Idiopathic pulmonary fibrosis
2017 Standout
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
2006
Consensus conference on mechanical ventilation-January 28–30, 1993 at Northbrook, Illinois, USA
1994
Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension
2016
Pulmonary veno-occlusive disease
2016
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
2005 Standout
The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension
2011
Medical Therapy For Pulmonary Arterial Hypertension
2004
Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation
2012
Benfluorex and Unexplained Valvular Heart Disease: A Case-Control Study
2010
Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension
2002
Ventilation/perfusion lung scan in pulmonary veno-occlusive disease
2011
Medical Therapy for Pulmonary Arterial Hypertension
2007
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
2015
Treatment of Pulmonary Arterial Hypertension
2004 Standout
Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study
2007
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Pulmonary Arterial Hypertension
2009
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials
2007
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
2014
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
2007
Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension
2008
Evaluation of a Ventilation Strategy to Prevent Barotrauma in Patients at High Risk for Acute Respiratory Distress Syndrome
1998 Standout
Definitions and Diagnosis of Pulmonary Hypertension
2013 Standout
Genetics of pulmonary hypertension: from bench to bedside
2002
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards
2014
Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension
2004
Advances in the treatment of secondary pulmonary hypertension
2003
Effect of Mechanical Ventilation on Inflammatory Mediators in Patients With Acute Respiratory Distress Syndrome
1999 Standout
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era
2005
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients
2012
Systemic sclerosis
2017 Standout
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study
2011
Low-dose Almitrine Bismesylate in the Treatment of Hypoxemia due to Chronic Obstructive Pulmonary Disease
1994
Clinical classification of pulmonary hypertension
2004 Standout
Survival with first-line bosentan in patients with primary pulmonary hypertension
2005
Six-Minute Walk Test and Health Status Assessment in Sarcoidosis
2007
Pulmonary Arterial Hypertension
2006
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
2011 Standout
Scleroderma
2009 Standout
Primary pulmonary hypertension
2003
Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger???s Syndrome
2008
Angiogenesis in health and disease
2003 Standout
Chronic Thromboembolic Pulmonary Hypertension: Pre- and Postoperative Assessment with Breath-hold MR Imaging Techniques
2004
Sarcoidosis
2013 Standout
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
2005
Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension
2007
Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension
2005
Antithrombotic Therapy for VTE Disease
2012 Standout
Effects of positive end-expiratory pressure on hyaline membrane formation in a rabbit model of the neonatal respiratory distress syndrome
1988
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
2004 Standout
Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension
2006
Pathobiology of pulmonary arterial hypertension
2002
Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility
2013
Air Pollution and Heart Rate Variability
2008
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
2009
Effect of a Protective-Ventilation Strategy on Mortality in the Acute Respiratory Distress Syndrome
1998 Standout
The Current Treatment of Pulmonary Arterial Hypertension
2006
Diagnosis and Assessment of Pulmonary Arterial Hypertension
2009
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
2004
Bladder cancer
2016 Standout
Hemodynamic Observations in Two Pulmonary Hypertensive Patients Changing Treatment From Inhaled Iloprost to the Oral Endothelin-Antagonist Bosentan
2005
Bosentan Therapy for Pulmonary Arterial Hypertension
2002 Standout
Driving Pressure and Survival in the Acute Respiratory Distress Syndrome
2015 Standout
Updated Clinical Classification of Pulmonary Hypertension
2013 Standout
Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension
2011
Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis
2000
The Emerging Role of Magnetic Resonance Imaging in the Diagnosis and Management of Pulmonary Hypertension
2008
Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension
2009 StandoutNobel
Sickle-cell disease
2010 Standout
Bosentan therapy for portopulmonary hypertension
2005
Ambrisentan Therapy for Pulmonary Arterial Hypertension
2005
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
2008
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
2007
Ventilator-Induced Lung Injury
2013 Standout
Histologic aspects of pulmonary barotrauma in critically ill patients with acute respiratory failure
1993
CLINICAL CLASSIFICATION OF PULMONARY HYPERTERNSION
2001
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
2003
Portopulmonary Hypertension
2014
Pulmonary Arterial Hypertension
2004
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
2008
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
2015 Standout
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
2005
Idiopathic pulmonary fibrosis
2011 Standout
What’s new in the treatment of portopulmonary hypertension?
2015
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension
2005
Transient Receptor Potential Cation Channels in Disease
2007 Standout
The increase in pulmonary arterial pressure caused by hypoxia depends on iron status
2008 StandoutNobel
Portopulmonary hypertension and hepatopulmonary syndrome
2004
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
2013
Chronic thromboembolic pulmonary hypertension
2014
Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis
2007
Introduction
2004
Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers
2006
ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre
2011
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2001 Standout
Sitaxsentan Therapy for Pulmonary Arterial Hypertension
2003
Chemokine RANTES in Severe Pulmonary Arterial Hypertension
2002
Bosentan Inhibits Transient Receptor Potential Channel Expression in Pulmonary Vascular Myocytes
2004
Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
2004
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
2011
Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
2006
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Pulmonary Arterial Hypertension in France
2006 Standout
Mechanical Ventilation
1993
Selective Upregulation of Endothelin B Receptor Gene Expression in Severe Pulmonary Hypertension
2002
Pulmonary Vascular Disease in Adults With Congenital Heart Disease
2007
Pulmonary Arterial Hypertension
2006
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
2002 Standout
Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease
2011 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit
2005
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome
2000 Standout
Right Ventricular Function in Cardiovascular Disease, Part I
2008 Standout
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
2005
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009 Standout
Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension
2013
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Effectiveness of Phosphodiesterase‐5 Inhibitor Therapy for Portopulmonary Hypertension
2015
Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival
2003
Works of G Simonneau being referenced
Pulmonary Arterial Resistance: Noninvasive Measurement with Indexes of Pulmonary Flow Estimated at Velocity-encoded MR Imaging—Preliminary Experience
1999
Fenfluramine-like cardiovascular side-effects of benfluorex
2009
Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension
2010
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
2001 Standout
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
2012
Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives
1998
[Gas exchange, static pressure-volume curve and positive-pressure ventilation at the end of expiration. Study of 16 cases of acute respiratory insufficiency in adults].
1981
A single orally administered dose of almitrine improves pulmonary gas exchange during exercise in patients with chronic air-flow obstruction.
1986
[Pulmonary artery hypertension associated with connective tissue diseases].
2003
Factors Influencing Pulmonary Volumes and CO2 Elimination during High-frequency Jet Ventilation
1985
[Pulmonary arterial hypertension of chronic thrombo-embolic origin. 70 patients].
1994
[Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications].
1994
[Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension].
2008